Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,990,660
  • Shares Outstanding, K 73,487
  • Annual Sales, $ 57,990 K
  • Annual Income, $ -134,230 K
  • 60-Month Beta 2.04
  • Price/Sales 205.71
  • Price/Cash Flow N/A
  • Price/Book 5.48
Trade NTLA with:

Options Overview Details

View History
  • Implied Volatility 101.32% ( +6.85%)
  • Historical Volatility 54.85%
  • IV Percentile 70%
  • IV Rank 53.73%
  • IV High 135.80% on 06/22/21
  • IV Low 61.29% on 11/12/21
  • Put/Call Vol Ratio 1.38
  • Today's Volume 442
  • Volume Avg (30-Day) 520
  • Put/Call OI Ratio 1.17
  • Today's Open Interest 4,517
  • Open Int (30-Day) 4,707

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.91
  • Number of Estimates 10
  • High Estimate -0.64
  • Low Estimate -1.12
  • Prior Year -0.69
  • Growth Rate Est. (year over year) -31.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
78.50 unch
on 01/24/22
126.95 -38.16%
on 12/31/21
-48.31 (-38.10%)
since 12/23/21
3-Month
78.50 unch
on 01/24/22
143.92 -45.45%
on 11/08/21
-53.03 (-40.32%)
since 10/22/21
52-Week
43.86 +78.98%
on 03/05/21
202.73 -61.28%
on 06/30/21
+4.14 (+5.57%)
since 01/22/21

Most Recent Stories

More News
Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug

Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.

EDIT : 17.60 (-3.03%)
NTLA : 78.50 (-3.70%)
CRSP : 60.02 (-4.14%)
ANAB : 30.99 (-0.39%)
5 Charts to Remember if the Stock Market Crashes in 2022

Lessons from the past can guide investors if history is repeating.

NTLA : 78.50 (-3.70%)
MRNA : 151.42 (-5.41%)
CSCO : 57.03 (+0.62%)
TSLA : 889.00 (-5.82%)
Intellia (NTLA) Inks Deal With Kyverna for Autoimmune Diseases

Intellia (NTLA) inks a licensing and collaboration deal with Kyverna Therapeutics for developing an allogeneic CAR T-cell therapy for autoimmune diseases.

REGN : 619.85 (-0.25%)
ICPT : 14.90 (-3.31%)
VTVT : 0.7700 (+0.14%)
NTLA : 78.50 (-3.70%)
Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022

Advance clinical development of NTLA-2001, a potential single-dose therapy for transthyretin (ATTR) amyloidosis; on track to present additional data from...

NTLA : 78.50 (-3.70%)
Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on...

NTLA : 78.50 (-3.70%)
Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases

— Intellia grants Kyverna exclusive rights to its differentiated allogeneic cell engineering platform for the development of KYV-201, a next-generation...

NTLA : 78.50 (-3.70%)
Intellia's (NTLA) CRISPR Therapies Show Promise Amid Competition

While Intellia's (NTLA) pipeline is in early-stage clinical studies, its development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.

REGN : 619.85 (-0.25%)
NTLA : 78.50 (-3.70%)
CRSP : 60.02 (-4.14%)
DTIL : 4.61 (+0.44%)
5 Biotech Stocks That More Than Doubled This Year

The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplary...

DVAX : 12.60 (-2.02%)
MRNA : 151.42 (-5.41%)
PRTA : 35.23 (-0.56%)
NTLA : 78.50 (-3.70%)
BNTX : 141.07 (-4.36%)
Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?

Style Box ETF report for IWO

IWO : 246.50 (+0.05%)
LSCC : 52.90 (-1.87%)
CROX : 98.50 (-3.56%)
IJT : 122.40 (-1.61%)
NTLA : 78.50 (-3.70%)
VBK : 238.92 (-2.02%)
Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer

CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing...

NTLA : 78.50 (-3.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with...

See More

Key Turning Points

3rd Resistance Point 92.41
2nd Resistance Point 90.10
1st Resistance Point 85.81
Last Price 78.50
1st Support Level 79.21
2nd Support Level 76.90
3rd Support Level 72.61

See More

52-Week High 202.73
Fibonacci 61.8% 142.04
Fibonacci 50% 123.29
Fibonacci 38.2% 104.55
Last Price 78.50
52-Week Low 43.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar